What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2022-08-15 compared with 2022-05-16 · 73 added, 14 removed, 11 unchanged (89% of the section changed)

1 unchanged sentence

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Exhibit Number Description

2.1 Business Combination Agreement, dated as of December 19, 2021, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc.

and Senti Biosciences, Inc.

(attached as Annex A to the Registration Statement).

2.2 Amendment No.

1 to Business Combination Agreement, dated as of February 12, 2022, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc.

and Senti Biosciences, Inc.

(attached as Annex AA to the Registration Statement).

2.3 Amendment No.

2 to Business Combination Agreement, dated as of May 19, 2022, by and among Dynamics Special Purpose Corp., Explore Merger Sub, Inc.

and Senti Biosciences, Inc.

3.1 Amended and Restated Certificate of Incorporation of Senti Biosciences, Inc.

3.2 Amended and Restated Bylaws of Senti Biosciences, Inc.

4.1 Specimen Common Stock Certificate .

10.1 Note Subscription Agreement by and among Senti Biosciences, Inc., Dynamics Special Purpose Corp.

and Bayer HealthCare LLC, dated as of May 19, 2022.

10.2 Senti Biosciences, Inc.

2016 Stock Incentive Plan, as amended, and forms of award agreements thereunder.

10.3* Senti Biosciences, Inc.

2022 Stock Option and Incentive Plan and forms of award agreements thereunder.

10.4* Senti Biosciences, Inc.

2022 Employee Stock Purchase Plan.

10.5 Form of Indemnification Agreement by and between the Registrant and each of its directors and executive officers.

10.6 Employee Offer Letter, by and between Timothy Lu and Senti Biosciences, Inc., dated December 27, 2018.

10.7 Employee Offer Letter, by and between Philip Lee and Senti Biosciences, Inc., dated December 27, 2018.

10.8 Employment Agreement, by and between Curt Herberts III and Senti Biosciences, Inc., dated April 28, 2018.

10.9 Employee Offer Letter, by and between Deborah Knobelman and Senti Biosciences, Inc., dated May 13, 2021.

10.10 Lease, by and between Britannia Biotech Gateway Limited Partnership and Senti Biosciences, Inc., dated July 17, 2018.

10.11 First Amendment to Lease, by and between Britannia Biotech Gateway Limited Partnership and Senti Biosciences, Inc., dated May 8, 2019 .

10.12 Second Amendment to Lease, by and between Britannia Biotech Gateway Limited Partnership and Senti Biosciences, Inc., dated June 17, 2020.

10.13 Research and Development and Laboratory Lease Agreement, by and between 1430 Harbor Bay Pkwy LLC and Senti Biosciences, Inc., dated June 3, 2021.

10.14 Patent License Agreement by and between the U.S.

Department of Health and Human Services, as represented by the National Cancer Institute, and Senti Biosciences, Inc., dated July 20, 2020.

10.15 Patent License Agreement by and between the U.S.

Department of Health and Human Services, as represented by the National Cancer Institute, and Senti Biosciences, Inc., dated February 5, 2021.

10.16 Research Collaboration and License Agreement by and between Spark Therapeutics, Inc.

and Senti Biosciences, Inc., dated April 9, 2021 .

Exhibit Number Description

10.17 Patent License Agreement by and between the U.S.

Department of Health and Human Services, as represented by the National Cancer Institute, and Senti Biosciences, Inc., dated May 17, 2021.

10.18 Collaboration and Option Agreement by and between BlueRock Therapeutics, LP and Senti Biosciences, Inc., dated May 21, 2021.

10.19 Investor Rights and Lock-up Agreement.

10.20 Form of Subscription Agreement.

10.21 Form Sponsor Support Agreement (included in Exhibit 2.1).

10.22 Form of Company Stockholder Support Agreement (included in Exhibit 2.1).

10.23 Form of Amendment to Company Stockholder Support Agreement entered into on February 12, 2022 by certain stockholders of Senti Biosciences, Inc.

(incorporated by reference to and Exhibit 10.1 of Dynamics Special Purpose Corp.’s Current Report on Form 8-K as filed with the SEC on February 15, 2021).

31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

4 unchanged sentences

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

Inline XBRL Taxonomy Extension Schema Document

Inline XBRL Taxonomy Extension Calculation Linkbase Document

Inline XBRL Taxonomy Extension Definition Linkbase Document

Inline XBRL Taxonomy Extension Label Linkbase Document

Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.INS* Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH* Inline XBRL Taxonomy Extension Schema Document

101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document

104* The cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101.

___________________

* Filed herewith.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dynamics Special Purpose Corp.

/s/ Mostafa Ronaghi

Mostafa Ronaghi

Chief Executive Officer

Dynamics Special Purpose Corp.

/s/ Mark Afrasiabi

Mark Afrasiabi

** Furnished herewith.

This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section.

Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

(1) Previously filed as an exhibit to Amendment No.

3 to our Registration Statement on Form S-4 filed on May 10, 2022 and incorporated herein by reference.

(2) Previously filed as an exhibit to our Current Report on Form 8-K filed on May 24, 2022 and incorporated herein by reference.

(3) Previously filed as an exhibit to our Current Report on Form 8-K filed on June 15, 2022 and incorporated herein by reference.

(4) Previously filed as an exhibit to our Registration Statement on Form S-4 filed on February 14, 2022 and incorporated herein by reference.

(5) Previously filed as an exhibit to Amendment No.

1 to our Registration Statement on Form S-4 filed on April 1, 2022 and incorporated herein by reference.

(6) Previously filed as an exhibit to our Registration Statement on Form S-1 filed on June 28, 2022 and incorporated herein by reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 15th day of August, 2022.

August 15, 2022

SENTI BIOSCIENCES, INC.

/s/ Timothy Lu, M.D., Ph.D.

Timothy Lu, M.D., Ph.D.

Chief Executive Officer & President

/s/ Deborah Knobelman, Ph.D.

Deborah Knobelman, Ph.D.

Chief Financial Officer

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information